Opus Genetics, Inc. (Nasdaq: IRD) announced it has completed patient enrollment in its registrational Phase 3 clinical trial evaluating OPGx-LCA5 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE